HHLR Advisors’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

HHLR Advisors’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-235,214	Closed	-$4.32M	–	107
2020 Q4	$4.32M	Hold	235,214	–	–	0.03%	89
2020 Q3	$4.31M	Hold	235,214	–	–	0.03%	79
2020 Q2	$3.52M	Hold	235,214	–	–	0.03%	68
2020 Q1	$3.72M	Hold	235,214	–	–	0.05%	55
2019 Q4	$3.82M	Hold	235,214	–	–	0.05%	51
2019 Q3	$3.5M	Buy	+235,214	New	+$3.17M	0.05%	57

HHLR Advisors's CBMG Position: Q1 2021 in Review

HHLR Advisors sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 235,214 shares — an estimated $4.32M sold.

HHLR Advisors first reported a position in CBMG in Q3 2019 and held it in 6 quarters. The position peaked at $4.32M in Q4 2020. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.

HHLR Advisors reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
HHLR Advisors sold 235,214 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $4.32M.
HHLR Advisors first reported a position in Cellular Biomedicine Group, Inc. in Q3 2019 and held it in 6 quarters.
HHLR Advisors's Cellular Biomedicine Group, Inc. position peaked at $4.32M in Q4 2020.
0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.

Based on HHLR Advisors's 13F filing for Q1 2021, filed 17 May 2021.